Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2022-03-29 Purchase |
2022-03-31 8:15 pm |
AN2 Therapeutics Inc. | ANTX | Readnour Robin Shane Director |
153,334 | $15 | $2,300,010 | 487,592 (Indirect) |
View |
| 2022-03-29 Purchase |
2022-03-31 8:15 pm |
AN2 Therapeutics Inc. | ANTX | Adjuvant Global Health Technology Fund L.P. Adjuvant Global Health Technology Fund DE L.P. 10% Owner |
166,666 | $15 | $2,499,990 | 2,210,735 (Indirect) |
View |
| 2022-03-29 Purchase |
2022-03-31 8:15 pm |
AN2 Therapeutics Inc. | ANTX | Aziz Kabeer Director 10% Owner |
166,666 | $15 | $2,499,990 | 2,210,735 (Indirect) |
View |
| 2022-03-29 Purchase |
2022-03-31 4:31 pm |
AN2 Therapeutics Inc. | ANTX | RA CAPITAL MANAGEMENT L.P. RA Capital Healthcare Fund LP RA Capital Nexus Fund II L.P. Kolchinsky Peter Shah Rajeev M. 10% Owner |
1,666,666 | $15 | $24,999,990 | 415,612 (Indirect) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2022-03-29 Conversion |
2022-03-31 8:15 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Zakrzewski Joseph S Director |
98,199 | $0 | 98,199 (Direct) |
View |
| 2022-03-29 Conversion |
2022-03-31 8:15 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Readnour Robin Shane Director |
751,621 | $0 | 487,592 (Indirect) |
View |
| 2022-03-29 Conversion |
2022-03-31 8:15 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Adjuvant Global Health Technology Fund L.P. Adjuvant Global Health Technology Fund DE L.P. 10% Owner |
2,430,714 | $0 | 2,210,735 (Indirect) |
View |
| 2022-03-29 Conversion |
2022-03-31 8:15 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Easom Eric Chief Executive Officer |
4,907 | $0 | 4,907 (Direct) |
View |
| 2022-03-29 Conversion |
2022-03-31 8:15 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Aziz Kabeer Director 10% Owner |
2,430,714 | $0 | 2,210,735 (Indirect) |
View |
| 2022-03-29 Conversion |
2022-03-31 4:31 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | RA CAPITAL MANAGEMENT L.P. RA Capital Healthcare Fund LP RA Capital Nexus Fund II L.P. Kolchinsky Peter Shah Rajeev M. 10% Owner |
1,999,997 | $0 | 415,612 (Indirect) |
View |
Ownership |
2022-03-24 9:27 pm |
N/A 2030-01-22 |
AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer |
0 | $0 | 141,174 (Direct) |
View |
Ownership |
2022-03-24 9:27 pm |
N/A 2032-02-17 |
AN2 Therapeutics Inc. | ANTX | Spigelman Melvin K Director |
0 | $0 | 16,941 (Direct) |
View |
Ownership |
2022-03-24 9:27 pm |
N/A 2031-04-29 |
AN2 Therapeutics Inc. | ANTX | Martin Patricia A. Director |
0 | $0 | 24,999 (Direct) |
View |
Ownership |
2022-03-24 9:26 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Zakrzewski Joseph S Director |
0 | $0 | 704,078 (Indirect) |
View |
Ownership |
2022-03-24 9:25 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Eckburg Paul Chief Medical Officer |
0 | $0 | 141,706 (Direct) |
View |
Ownership |
2022-03-24 9:24 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Aziz Kabeer Director |
0 | $0 | 2,430,714 (Indirect) |
View |
Ownership |
2022-03-24 9:23 pm |
N/A 2031-08-18 |
AN2 Therapeutics Inc. | ANTX | Nazak Michael Adrian Chief Accounting Officer |
0 | $0 | 65,882 (Direct) |
View |
Ownership |
2022-03-24 9:22 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | RA CAPITAL MANAGEMENT L.P. RA Capital Healthcare Fund LP RA Capital Nexus Fund II L.P. Kolchinsky Peter Shah Rajeev M. 10% Owner |
0 | $0 | 1,999,997 (Indirect) |
View |
Ownership |
2022-03-24 9:22 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Marks Gilbert Lynn Director |
0 | $0 | 33,495 (Direct) |
View |
Ownership |
2022-03-24 9:21 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Readnour Robin Shane Director |
0 | $0 | 751,621 (Indirect) |
View |
Ownership |
2022-03-24 9:19 pm |
N/A 2030-01-22 |
AN2 Therapeutics Inc. | ANTX | Day Lucy Chief Financial Officer |
0 | $0 | 141,668 (Direct) |
View |
Ownership |
2022-03-24 9:19 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Easom Eric Chief Executive Officer |
0 | $0 | 1,549,019 (Indirect) |
View |
Ownership |
2022-03-24 9:19 pm |
N/A 2030-01-22 |
AN2 Therapeutics Inc. | ANTX | Chanda Sanjay Chief Development Officer |
0 | $0 | 141,581 (Direct) |
View |
Ownership |
2022-03-24 9:16 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Adjuvant Global Health Technology Fund L.P. Adjuvant Global Health Technology Fund DE L.P. 10% Owner |
0 | $0 | 2,430,714 (Indirect) |
View |
Ownership |
2022-03-24 9:16 pm |
N/A 2031-04-29 |
AN2 Therapeutics Inc. | ANTX | Wong Stephanie Director |
0 | $0 | 24,999 (Direct) |
View |